The T Cell Receptor (TCR) market is a subset of the biopharmaceutical industry that focuses on the development of therapeutics that target T cells. T cells are a type of white blood cell that play a key role in the body's immune system. TCRs are proteins that are expressed on the surface of T cells and are responsible for recognizing and binding to antigens. Therapeutics that target TCRs are being developed to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. The TCR market is a rapidly growing field, with many companies investing in research and development. Companies are developing novel TCR-based therapies, such as chimeric antigen receptor T cell (CAR-T) therapies, which are designed to target specific antigens on cancer cells. Additionally, companies are exploring the use of TCRs to develop vaccines and immunotherapies. Some companies in the TCR market include Kite Pharma, Juno Therapeutics, Adaptimmune, and Cellectis. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.